



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1614
RECEIVED


Applicant: Yiv et al.
Serial No.: 09/957,434
Filed: 9/19/01
Title: GEL-MICROEMULSION FORMULATIONS

Examiner: Not yet assigned
Group Art Unit: 1614
Docket: 12152.48US11

JAN 28 2002

TECH CENTER 1600/2900

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence and the paper(s), as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: IDS, Commissioner for Patents, Washington, D.C. 20231, on January 22, 2002.

By: 
Karen Olsen

IDS
Commissioner for Patents
Washington, D.C. 20231


Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Information Disclosure Statement, Form 1449, 124 Reference(s)
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.
P.O. Box 2903, Minneapolis, MN 55402-0903
612.332.5300

By: 
Name: Brian C. Whipps
Reg. No.: 43,261
BCW:ko



RECEIVED

JAN 30 2002

OFFICE OF PETITIONS



RECEIVED

JAN 28 2002

#6

TECH CENTER 1600/2900
PATENT

S/N 09/957,434

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Yiv et al.	Examiner:	Not yet assigned
Serial No.:	09/957,434	Group Art Unit:	1614
Filed:	9/19/01	Docket No.:	12152.48USI1
Title:	GEL-MICROEMULSION FORMULATIONS		

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence and the paper(s), as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on January 28, 2002.

By:

Karen Olsen

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. At least some of the references were recently cited in an International Search Report mailed 9/7/2000.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided. Enclosed for the Examiner's information is a copy of the International Search Report.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked

as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,
MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903
612.332.5300

Date: 1-15-02


Brian C. Whipps
Reg. No. 43,261

RECEIVED

JAN 3 0 2002

OFFICE OF PETITIONS



FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

12152.48US11

Application Number:

09/957,434

Applicant: Yiv et al.

Filing Date: 9/19/01

Group Art Unit: 1614



TECH CENTER 1600/2900

JAN 24 2002

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	Re 36,256	7/20/1999	Spada et al.			
	3,850,939	11/26/1974	Elslager et al.			
	3,970,725	7/20/1976	Tugukuni et al.			
	4,938,949	7/3/1990	Borch et al.			
	4,992,271	2/12/1991	Fernandes et al.			
	5,069,906	12/3/1991	Cohen et al.			
	5,198,333	3/30/1993	Dewanckele et al.			
	5,314,685	5/24/1994	Tyle et al.			
	5,411,963	5/2/1995	Dreikorn et al.			
	5,449,678	9/12/1995	Pines et al.			
	5,457,105	10/10/95	Barker			
	5,468,898	11/21/1995	Huang et al.			
	5,712,237	2/24/1998	Myers et al.			
	5,792,771	8/11/1998	App et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	0 082 385	12/4/1982	Europe				
	WO 94/03157	7/23/1993	PCT				
	WO 95/07696	8/30/1994	PCT				
	WO 95/15758	12/8/1994	PCT				
	WO 95/24190	3/6/1995	PCT				
	WO 95/31969	4/28/1995	PCT				
	WO 96/06616	8/29/1995	PCT				
	WO 96/22976	12/22/1995	PCT				
	WO 96/33745	4/17/1996	PCT				
	WO 96/39143	6/4/1996	PCT				

RECEIVED

JAN 30 2002

OFFICE OF PETITIONS

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.48USII	Application Number: 09/957,434
	Applicant: Yiv et al.	
	Filing Date: 9/19/01	Group Art Unit: 1614

WO 96/40113	6/7/1996	PCT				
WO 96/40116	6/5/1996	PCT				
WO 96/40648	6/4/1996	PCT				
WO 98/38984	3/4/1998	PCT				
WO 98/51284	5/12/1998	PCT				
WO 99/10325	8/4/1998	PCT				
WO 99/36063	2/20/1998	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Andrews et al., <i>J. American Veterinary Medicine Association</i> , Vol. 202, No. 4, pp. 229-249, 1993 Report of the AVMA Panel of Euthanasia
	Augenbraun MH, et al., <i>Infect Dis Clin North Am</i> , 1994; 8:439-48 Sexually Transmitted Diseases in HIV-Infected Persons
	Brassinne et al., <i>JNCI</i> , Vol. 70, No. 6, pp. 1081-1087 Antitumor Activity of a Water-Insoluble Compound Entrapped in Liposomes on L1210 Leukemia in Mice
	Castle et al., <i>Biol. Reprod.</i> , 1997, 56:153-159 Contraceptive Effect of Sperm-Agglutinating Monoclonal Antibodies in Rabbits
	Castle et al., <i>Contraception</i> , 1998, 58:51-60 Contraceptive Testing of Vaginal Agents in Rabbits
	Cerutti et al., <i>Cancer Cells</i> , Vol., 3, No. 1, pp. 1-7 Inflammation and Oxidative Stress in Carcinogenesis
	Chantler E., <i>Brit Fam Plann</i> , 1992;17:118-9 Vaginal spermicides: some current concerns
	Charman et al., <i>Pharmaceutical Research</i> , Vol. 9, No. 1, pp. 87-93, 1992 Self-Emulsifying Drug Delivery Systems: Formulation and Biopharmaceutic Evaluation of an Investigational Lipophilic Compound
	Constantinides, <i>Pharmaceutical Research</i> , Vol. 12, No. 11, pp. 1561-1572, 1995 Lipid Microemulsions for Improving Drug Dissolution and Oral Absorption: Physical and Biopharmaceutical Aspects
	Danel et al., 1997, <i>Acta Chemica Scandinavica</i> , 51(3):426-430 Anti-HIV Active Naphthyl Analogues of HEPT and DABO
	Danel et al., 1998, <i>J. Med. Chem.</i> , 41:191-198 Synthesis and Anti-HIV-1 Activity of Novel 2,3-Dihydro-7H-thiazolo[3,2- α]pyrimidin-7-ones
	Darnell et al., <i>Science</i> , Vol. 264, pp. 1415-1421 Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins
	D'Cruz et al., 1995, <i>Biology of Reproduction</i> , 53(5):1118-1130 B2-Integrin (CD11b/CD18) is the Primary Adhesive Glycoprotein Complex Involved in Neutrophil-Mediated Immune Injury to Human Sperm
	D'Cruz et al., 1998, <i>Biology of Reproduction</i> , 4(7), pp. 683-693 Spermicidal Activity of Chelated Complexes of bis(cyclopentadienyl)vanadium(IV)

RECEIVED

JAN 30 2002

OFFICE OF PETITIONS

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 0449 INFORMATION DISCLOSURE STATEMENT JAN 24 2002 PATENT & TRADEMARK OFFICE	Docket Number: 12152.48USII		Application Number: 09/957,434
	Applicant: Yiv et al.		
	Filing Date: 9/19/01	Group Art Unit: 1614	

IN AN APPLICATION
(Use several sheets if necessary)

	D'Cruz et al., 1998, <i>Biology Reproduction</i> , 58:1515-1528 Spermicidal Activity of Metallocene Complexes Containing Vanadium(IV) in Humans
9	D'Cruz et al., 1998, <i>Biology Reproduction</i> , 59:503-515 Aryl Phosphate Derivatives of Bromo-Methoxy-Azidothymidine Are Dual-Function Spermicides with Potent Anti-Human Immunodeficiency Virus
	D'Cruz et al., 1999, <i>Biology of Reproduction</i> , 60:1419-1428 Novel Derivatives of Phenethyl-5-Bromopyridylthiourea and Dihydroalkoxybenzyl-oxopyrimidine Are Dual-Function Spermicides with Potent Anti-Human Immunodeficiency Virus Activity
	D'Cruz et al., 1999, <i>Biology Reproduction</i> , 60(2), pp. 345-444 Spermicidal activity of oxovanadium(IV) complexes of 1, 10-phenanthroline, 2,2'-bipyridyl, 5'-bromo-2-hydroxyacetophenone and derivatives in humans
	D'Cruz et al., <i>Biol. Reprod.</i> , 2001, 64(1), 51-59 Thymidine Kinase-Independent Intracellular Delivery of Bioactive Nucleotides by Aryl Phosphate Derivatives of Bromo-Methoxy Zidovudine (Compounds WHI-05 and WHI07) in Normal Human Female Genital Tract Epithelial Cells and Sperm
9	D'Cruz et al., <i>Biology of Reproduction</i> , Vol. 62, pp. 37-44, 2000 Structural Requirements for Potent Human Spermicidal Activity of Dual-Function Aryl Phosphate Derivative of Bromo-Methoxy Zidovudine (Compound WHI-07)
	D'Cruz et al., <i>Contraception</i> , 1999, 59(5):319-331 WHI-05, a Novel Bromo-methoxy Substituted Phenyl Phosphate Derivative of Zidovudine, Is a Dual-Action Spermicide with Potent Anti-HIV Activity
	D'Cruz et al., <i>Contraception</i> , 2000, 61(1), 69-76 Evaluation of Subchronic (13 Weeks) and Reproductive Toxicity Potential of Intravaginal Gel-Microemulsion Formulation of a Dual-Function Phenyl Phosphate Derivative of Bromo-Methoxy Zidovudine (Compound WHI-05) in B ₆ C ₃ F ₁ Mice
	D'Cruz et al., <i>Molecular Human Reproduction</i> , Vol. 5, No. 5, pp. 421-432, 1999 Synthesis, characterization and preclinical formulation of a dual-action phenyl phosphate derivative of bromo-methoxy zidovudine (compound WHI-07) with potent anti-HIV and spermicidal activities.
	de Jong, <i>Therapie</i> , 1999, 54:11-14 The safety of pharmaceutical excipients
	Diehl et al., <i>J. Virol</i> , 1995, 69:2328-2332 Longitudinal Assessment of Feline Immunodeficiency Virus Kinetics in Plasma by Use of a Quantitative Competitive Reverse Transcriptase PCR
	Digenis GA, et al., <i>Pharm Dev Technol</i> , 1999;4:421-30 Novel Vaginal Controlled-Delivery Systems Incorporating Coprecipitates of Nonoxynol-9
	Eccleston GM, In: Swarbrick J. Boylan JC, eds. <i>Encyclopedia of Pharmaceutical Technology</i> , NY, Marcel Dekker, 1992:375-421 Microemulsions
	Eckstein et al., <i>J. Reprod Fertil.</i> , 1969, 20:85-93 Comparison of Vaginal Tolerance Tests of Spermicidal Preparations in Rabbits and Monkeys
	Fischer et al., <i>Science</i> , Vol. 253, No. 5018, pp. 401-406, 1991 Protein Tyrosine Phosphatases: A Diverse Family of Intracellular and Transmembrane Enzymes
	Folkman, <i>Journal of the National Cancer Institute</i> , Vol. 82, No. 1, pp. 4-6 What is the Evidence that Tumors are Angiogenesis Dependent?
	Furuse K, et al., <i>J Pharmacobiodyn</i> , 1983;6:359-72 Studies on Spermicidal Activity of Surfactants. ...
	Greene et al., <i>Arch Virol</i> , 1993, 133:51-62 Extensive sequence variation of feline immunodeficiency virus env genes in isolates from naturally infected cats
	Hamawy et al., 1995, <i>Cellular Signalling</i> , 7(6):535-544 Protein Tyrosine Phosphorylation as a Mechanism of Signalling in Mast Cells and Basophils

RECEIVED

JAN 30 2002

OFFICE OF PETITIONS

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.48USII	Application Number: 09/957,434
	Applicant: Yiv et al.	
	Filing Date: 9/19/01	Group Art Unit: 1614

	✓	Heidin, <i>Cell</i> , Vol. 80, pp. 213-223, 1995 Dimerization of Cell Surface Receptors in Signal Transduction
	✓	Helenious A, et al., <i>Biochem Biophys Acta</i> , 1975;415:29-79 Solubilization of Membranes by Detergents
	✓	Hira et al., <i>International Journal of STD & AIDS</i> , Vol. 8, pp. 243-250, 1997 Condom and nonoxynol-9 use and the incidence of HIV infection in serodiscordant couples in Zambia
	✓	Hooten TM, et al., <i>JAMA</i> , 1991;265:64-9 Escherichia coli Bacteriuria and Contraceptive Method
	✓	Hunter, <i>Cell</i> , Vol. 58, pp. 1013-1015, 1989 Protein-Tyrosine Phosphatases: The Other Side of the Coin
	✓	Hynes et al., <i>Journal of Heterocyclic Chemistry</i> , Vol. 25, No. 4, pp. 1173-1177, 1988 Direct Synthesis of 2,4-Diaminoquinazolines from 2-Fluorobenzonitriles
	✓	Hynes et al., <i>Journal of Heterocyclic Chemistry</i> , Vol. 28, No. 5, pp. 1357-1363, 1991 Further Studies on the Synthesis of Quinazolines from 2-Fluorobenzonitriles
	✓	International Search Report, PCT/US 00/07066, 8/11/2000
	✓	International Search Report, PCT/US 00/07419, 9/7/2000
	✓	Katz et al., <i>Proc. Nat'l. Acad. Sci. U.S.A.</i> , 1991, 88:10825-10829 Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex
	✓	Klagsbrun et al., <i>Current Biology</i> , Vol. 3, No. 10, pp. 699-702, 1993 VEGF/VPF: the angiogenesis factor found?
	✓	Kreiss et al., <i>JAMA</i> , Vol. 268, pp. 477-482, 1998 Efficacy of Nonoxynol 9 Contraceptive Sponge Use in Preventing Heterosexual Acquisition of HIV in Nairobi Prostitutes
	✓	Kulig JW, <i>Ped Clinic North Am</i> , 1989;36:717-30 Adolescent Contraception: Nonhormonal Methods
	✓	Kumar et al., 1994, <i>J. Med. Chem.</i> , 37:4297-4306 Synthesis, <i>in Vitro</i> , Biological Stability, and Anti-HIV Activity of 5-Halo-6-alkoxy(or azido)-5,6-dihydro-3'-azido-3'-deoxythymidine Diastereomers as Potential Prodrugs to 3'-Azido-3'-deoxythymidine (AZT)
	✓	Lundberg, <i>J. Pharm Pharmacol</i> , 1997, 49:16-21 A Submicron Lipid Emulsion Coated with Amphipathic Polyethylene Glycol for Parenteral Administration of Paclitaxel (Taxol)
	✓	Mai et al., 1997, <i>J. Med. Chem.</i> , 40(10):1447-1454 Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: Novel Non-Nucleoside Reverse Transcriptase Inhibitors of the S-DABO Series
	✓	Malaviya et al., 1999, <i>J. Bio. Chem.</i> , 274(38) 27028-27038 Targeting Janus Kinase 3 in Mast Cells Prevents Immediate Hypersensitivity Reactions and Anaphylaxis
	✓	McGuigan et al., 1993, <i>J. Med. Chem.</i> , 36:1048-1052 Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT
	✓	Mendez F, et al., <i>Contraception</i> , 1986;34:353-62 Use Effectiveness of a Spermicidal Suppository Containing Benzalkonium Chloride
	✓	Murhammer et al., <i>Biotechnology Progress</i> , 1990, Vol. 6, pp. 391-397 Sparged Animal Cell Bioreactors: Mechanism of Cell Damage and Pluronic F-68 Protection
	✓	Narla et al., <i>Clin. Cancer Res.</i> , 1998, 4:1405-1414 4-(3'-Bromo-4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: A Novel Quinazoline Derivative with Potent Cytotoxic Activity against Human Glioblastoma Cells
	✓	Narla et al., <i>Clin. Cancer Res.</i> , 1998, 4:2463-2471 Inhibition of Human Glioblastoma Cell Adhesion and Invasion by 4-(4'-Hydroxyphenyl)-amino-6,7-dimethoxyquinazoline

RECEIVED

JAN 30 2002

OFFICE OF PETITIONS

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449-P INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 12152.48US11	Application Number: 09/957,434
	Applicant: Yiv et al.	
	Filing Date: 9/19/01	Group Art Unit: 1614

		(WHI-P131) and 4-(3'-Bromo-4'hydroxyphenyl)-amino-6,7dimethoxyquinazoline (WHI-P154)
		Nerukar et al., <i>Pharmaceutical Research</i> , 1996, 13:528-534 The Use of Surfactants to Enhance the Permeability of Peptides Through Caco-2 Cells by Inhibition of an Apically Polarized Efflux System
		Niruthisard et al., <i>Sexually Transmitted Diseases</i> , Vol. 18, No. 3, pp. 176-179 The Effects of Frequent Nonoxynol-9 Use on the Vaginal and Cervical Mucosa
		Nomoto et al., 1990, <i>Chem. Pharm. Bull.</i> , 38(6):1591-1595 Studies on Cardiotonic Agents. I. Synthesis of Some Quinazoline Derivatives
		Nomoto et al., <i>Chem. Pharm. Bull.</i> , 1990, 38:1591-1595 Studies on Cardiotonic Agents. I. Synthesis of Some Quinazoline Derivatives
		Okada et al., <i>AIDS Res. Hum Retroviruses</i> , 1994, 10:1739-46 Superinfection of Cats with Feline Immunodeficiency Virus Subtypes A and B
		OTC Panel, <i>Federal Register</i> , 1980;45:82014-49
		Ozawa et al, 1993, <i>J. Bio. Chem.</i> , 268(3):1749-1756 Ca ²⁺ -dependent and Ca ²⁺ -independent Isozymes of Protein Kinase C Mediate Exocytosis in Antigen-stimulated Rat Basophilic RBL-2H3 Cells
		Patton DL, et al., <i>Sex Trans Dis</i> , 1996, 23:489-93 The Vaginal Microflora of Pig-Tailed Macaques and the Effects of Chlorhexidine and Benzalkonium on this Ecosystem
		Pawson, <i>Nature</i> , Vol. 373, No. 6515, pp. 573-580, 1995 Protein modules and signalling networks
		Plate et al., <i>Nature</i> , Vol. 359, No. 6398, pp. 845-848, 1992 Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas <i>in vivo</i>
		Pot et al., <i>Biochimica et Biophysica Acta</i> , Vol. 1136, pp. 35-43, 1992 A thousand and two protein tyrosine phosphatases
		Pouton, <i>Int'l J. of Pharmaceutics</i> , No. 27, pp. 335-348, 1985 Self-emulsifying drug delivery systems: assessment of the efficiency of emulsification
		Raymond et al., <i>Obstet Gynecol</i> , 1999, 93:896-903 Contraceptive Effectiveness of Two Spermidides: A Randomized Trial
		Rekart ML, <i>Defic Syndr</i> , 1992;5:425-27 The Toxicity and Local Effects of the Spermicide Nonoxynol 9
		Rey et al., <i>Biochem Biophys. Res. Commun.</i> , 1984, 121:126-33 Characterization of the RNA Dependent DNA Polymerase of a New Human T Lymphotropic Retrovirus (Lymphadenopathy Associated Virus)
		Ritschel, <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 1993, 13:205-20 Microemulsions for Improved Peptide Absorption from the Gastrointestinal Tract
		Roddy RE, et al., <i>Int J STD & HIV</i> , 1993;4:165-70 A dosing study of nonoxynol-9 and genital irritation
		Roddy RE, et al., <i>N Engl J Med</i> , 1998;339:504-10 A Controlled Trial of Nonoxynol 9 Film to Reduce Male-to-Female Transmission of Sexually Transmitted Diseases
		Rosenstein IJ, et al. <i>J Infect Dis</i> , 1998;177:1386-90 Effect on Normal Vaginal Flora of Three Intravaginal Microbicidal Agents Potentially Active Against Human Immunodeficiency Virus Type 1
		Saito et al., <i>Cell Growth & Differentiation</i> , Vol. 2, pp. 59-65, 1991 Molecular Characterization of Protein Tyrosine Phosphatases
		Sander et al., <i>Hum. Fertil</i> , 1941, 6:134-137 A Practical Method for Testing the Spermicidal Action of Chemical Contraceptives
		Schill WB, et al., <i>Andrologia</i> , 1981;13:42-9 Ultrastructure of Human Spermatozoa in the Presence of the Spermicide Nonoxynol-9 and a Vaginal Contraceptive Containing

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449*

INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

12152.48USII

Application Number:

09/957,434

Applicant: Yiv et al.

Filing Date: 9/19/01

Group Art Unit: 1614

		Nonoxinol-9
	°	Schlessinger et al., <i>Neuron</i> , Vol. 9, pp. 383-391, 1992 Growth Factor Signaling by Receptor Tyrosine Kinases
	°	Schwinn et al., <i>Journal of Radioanalytical and Nuclear Chemistry</i> , Vol. 232, Nos. 1-2, pp. 35-37, 1998 The effects of a thio-containing quinazolinone derivative (MECH) on the lipid oxidation in bilayer liposomes
	°	Stafford MK, <i>J Acquir Immune Defic Syndr Hum Retrovirol</i> , 1998;17:32731 Safety Study of Nonoxynol-9 as a Vaginal Microbicide: Evidence of Adverse Effects
	°	Sutherland, <i>Trends in Biology</i> , 1998, Vol. 16, pp. 41-46 Novel and Established Applications of Microbial Polysaccharides
	°	Taylor et al., <i>Annual Review, Cell Biology</i> , Vol. 8, pp. 429-462, 1992 Structural Framework for the Protein Kinase Family
	°	Tellier et al., <i>Veterinary Microbiology</i> , 1997, Vol. 57, p. 1-11 Development of FIV-specific Cytolytic T-lymphocyte Responses in Cats Upon Immunisation with FIV Vaccines
	°	Tenjaria, <i>Crit. Rev. Ther. Drug Carrier</i> , 1999, 16:461-521 Microemulsions: An Overview and Pharmaceutical Applications
	°	Trussell J, et al. <i>Stud Fam Plann</i> , 1987;18:23783 Contraceptive Failure in the United States: A Critical Review of the Literature
	°	Uckun et al., 1985, <i>Blut</i> , 50:19-23 Ex vivo elimination of neoplastic T-Cells from Human Marrow Using an Anti-M, 41,000 Protein Immunotoxin: Potentiation by ASTA Z7557
	°	Vig et al., 1998, <i>Bioorganic & Medicinal Chemistry Letters</i> 8:1461-1466 5-Alkyl-2-[(Methylthiomethyl)Thio]-6-(Benzyl)-Pyrimidine-4-(1H)-Ones as Potent Non-nucleoside Reverse Transcriptase Inhibitors of S-DABO Series
	°	Vig et al., 1998, <i>Bioorganic & Medicinal Chemistry</i> , 6:1789-1797 Rational Design and Synthesis of Phenethyl-5-bromopyridyl Thiourea Derivatives as Potent Non-nucleoside Inhibitors of HIV Reverse Transcriptase
	°	Weir et al., <i>Genitourin Med.</i> , Vol. 71, pp. 78-81, 1995 Nonoxynol-9 use, genital ulcers, and HIV infection in a cohort of sex workers
	°	Woodcock et al., <i>Cancer Res.</i> , 1990, 50:4199-4203 Reversal of the Multidrug Resistance Phenotype with Cremophor EL, a Common Vehicle for Water-insoluble Vitamins and Drugs
	°	Yiv et al., <i>Abstracts of Papers American Chemical Society</i> , Vol. 217, pp. 148, 1999 Microemulsion, liposome and mixed micellar formulations for a poorly water soluble quinazoline derivative
	°	Yiv et al., <i>Abstracts of Papers American Chemical Society</i> , Vol. 217, No. 12, pp. 015, 1999 Development of a vaginal cream for a novel anti-HIV spermicide.

RECEIVED

JAN 3 0 2002

OFFICE OF PETITIONS



23552

PATENT TRADEMARK OFFICE

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.